Case Study on Baby Monitor Exposures and Vulnerabilities - Rapid7

doi: x.1016/j.rmed.2020.106026. Epub 2020 May 13.

A study on infectivity of asymptomatic SARS-CoV-ii carriers

Affiliations

• PMID: 32513410
• PMCID: PMC7219423
• DOI: 10.1016/j.rmed.2020.106026

Complimentary PMC commodity

A study on infectivity of asymptomatic SARS-CoV-ii carriers

Ming Gao  et al. Respir Med. 2020 Aug .

Complimentary PMC commodity

Abstract

Background: An ongoing outbreak of coronavirus disease 2019 (COVID-xix) has spread effectually the earth. It is debatable whether asymptomatic COVID-nineteen virus carriers are contagious. We study hither a example of the asymptomatic patient and nowadays clinical characteristics of 455 contacts, which aims to report the infectivity of asymptomatic carriers.

Fabric and methods: 455 contacts who were exposed to the asymptomatic COVID-19 virus carrier became the subjects of our research. They were divided into three groups: 35 patients, 196 family members and 224 infirmary staffs. We extracted their epidemiological information, clinical records, auxiliary exam results and therapeutic schedules.

Results: The median contact time for patients was four days and that for family members was five days. Cardiovascular disease accounted for 25% among original diseases of patients. Autonomously from hospital staffs, both patients and family members were isolated medically. During the quarantine, 7 patients plus one family unit member appeared new respiratory symptoms, where fever was the about common one. The blood counts in most contacts were within a normal range. All CT images showed no sign of COVID-19 infection. No astringent acute respiratory syndrome coronavirus two (SARS-CoV-2) infections was detected in 455 contacts by nucleic acid exam.

Conclusion: In summary, all the 455 contacts were excluded from SARS-CoV-2 infection and we conclude that the infectivity of some asymptomatic SARS-CoV-2 carriers might be weak.

Keywords: Asymptomatic carrier; Contacts; Infectivity; SARS-CoV-ii.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Conflict of interest argument

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could accept appeared to influence the piece of work reported in this newspaper.

Figures

Fig. 1

Chest CT images of Case A. Figure a and c were taken on February xi, which showed non- COVID-19 imaging feature. Instance A underwent a CT scan once again on February 22. Figure b and d, the follow-upwardly images, showed no pregnant differences than earlier.

Similar manufactures

• Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.

  Khan M, Khan H, Khan South, Nawaz M. Khan M, et al. J Med Microbiol. 2020 Aug;69(8):1114-1123. doi: ten.1099/jmm.0.001231. J Med Microbiol. 2020. PMID: 32783802 Costless PMC commodity.

• Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China.

  Luo Y, Trevathan E, Qian Z, Li Y, Li J, Xiao W, Tu N, Zeng Z, Mo P, Xiong Y, Ye Thou. Luo Y, et al. Emerg Infect Dis. 2020 Aug;26(8):1930-1933. doi: 10.3201/eid2608.201016. Epub 2020 Apr 24. Emerg Infect Dis. 2020. PMID: 32330112 Free PMC article.

• Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe astute respiratory syndrome coronavirus 2 (SARS-CoV-two) infection among adults exposed to coronavirus illness (COVID-19): a structured summary of a report protocol for a randomised controlled trial.

  Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener K, Celum C, Wald A, Chu H, Wesche D, Baeten JM; Hydroxychloroquine COVID-nineteen PEP Study Squad. Barnabas RV, et al. Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-iv. Trials. 2020. PMID: 32493478 Free PMC article.

• Asymptomatic carrier state, acute respiratory disease, and pneumonia due to astringent acute respiratory syndrome coronavirus 2 (SARS-CoV-two): Facts and myths.

  Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Lai CC, et al. J Microbiol Immunol Infect. 2020 Jun;53(3):404-412. doi: 10.1016/j.jmii.2020.02.012. Epub 2020 Mar 4. J Microbiol Immunol Infect. 2020. PMID: 32173241 Free PMC article. Review.

• Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or but like SARS.

  Hon KL, Leung KKY, Leung AKC, Sridhar S, Qian S, Lee SL, Colin AA. Hon KL, et al. Pediatr Pulmonol. 2020 Jul;55(7):1584-1591. doi: 10.1002/ppul.24810. Epub 2020 Jun 1. Pediatr Pulmonol. 2020. PMID: 32483934 Free PMC article. Review.

Cited past 57 manufactures

• Oral Pathology in COVID-nineteen and SARS-CoV-two Infection-Molecular Aspects.

  Drozdzik A, Drozdzik M. Drozdzik A, et al. Int J Mol Sci. 2022 January 27;23(three):1431. doi: 10.3390/ijms23031431. Int J Mol Sci. 2022. PMID: 35163355 Complimentary PMC article. Review.

• Better strategies for containing COVID-19 pandemic: a report of 25 countries via a vSIADR model.

  Yan H, Zhu Y, Gu J, Huang Y, Lord's day H, Zhang X, Wang Y, Qiu Y, Xi Chen S. Yan H, et al. Proc Math Phys Eng Sci. 2021 Apr;477(2248):20200440. doi: ten.1098/rspa.2020.0440. Epub 2021 April 7. Proc Math Phys Eng Sci. 2021. PMID: 35153551 Free PMC article.

• Letter to the Editor concerning A study on infectivity of asymptomatic severe acute respiratory syndrome coronavirus ii (SARS-CoV2) carriers by Gao et al.

  Silverman EP, Reddy R, Ataya A, Eagan C. Silverman EP, et al. Respir Med. 2022 Jan;191:106061. doi: x.1016/j.rmed.2020.106061. Epub 2020 Jun nine. Respir Med. 2022. PMID: 35090689 Gratuitous PMC article. No abstruse available.

• Discovery of potential anti-SARS-CoV-2 drugs based on big-calibration screening in vitro and effect evaluation in vivo.

  Peng H, Ding C, Jiang Fifty, Tang W, Liu Y, Zhao L, Yi Z, Ren H, Li C, He Y, Zheng Ten, Tang H, Chen Z, Qi Z, Zhao P. Peng H, et al. Sci China Life Sci. 2021 Dec 24:i-17. doi: 10.1007/s11427-021-2031-7. Online ahead of print. Sci Red china Life Sci. 2021. PMID: 34962614 Free PMC article.

• The spatiotemporal manual dynamics of COVID-nineteen among multiple regions: a modeling written report in Chinese provinces.

  Jia Q, Li J, Lin H, Tian F, Zhu Chiliad. Jia Q, et al. Nonlinear Dyn. 2021 Oct 29:1-fifteen. doi: 10.1007/s11071-021-07001-1. Online ahead of impress. Nonlinear Dyn. 2021. PMID: 34728898 Free PMC article.

References

1. 1. Lescure F.X., Bouadma L., Nguyen D. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect. Dis. 2020;20 doi: 10.1016/S1473-3099(xx)30200-0. Published Online March 27 2020. - DOI - PMC - PubMed
2. 1. Adalja A.A., Toner E., Inglesby T.V. JAMA; 2020. Priorities for the Usa Health Community Responding to COVID-19. Published Online March 03 2020. Available at: - DOI - PubMed
3. 1. McCloskey B., Zumla A., Ippolito Yard. Mass gathering events and reducing further global spread of COVID-19: a political and public health dilemma. Lancet. 2020;395:1096–1099. doi: 10.1016/S0140-6736(xx)30681-4. - DOI - PMC - PubMed
4. 1. Globe Health Organization . 2020. Coronavirus Affliction (COVID-19) Outbreak.https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Available at:
5. 1. Lu R., Zhao 10., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-viii. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Medical

  • Genetic Alliance

• Miscellaneous

  • NCI CPTAC Assay Portal

tschidauncerew.blogspot.com

Source: https://pubmed.ncbi.nlm.nih.gov/32513410/

Share this post